靶向疟原虫环子孢子蛋白与蚊AgTRIO的多价肽疫苗
研究开发了含恶性疟原虫环子孢子蛋白(PfCSP)与蚊唾液蛋白AgTRIO片段的嵌合肽PfAg,免疫小鼠后产生针对两者的强效体液免疫。C57BL/6和CD-1小鼠经表达PfCSP的伯氏疟原虫感染蚊暴露后,PfAg免疫组生存率显著优于对照组。
要点
- PfAg嵌合肽可同时诱导抗PfCSP和抗AgTRIO的体液免疫
- 免疫后两种品系小鼠在疟原虫感染蚊暴露下生存率显著改善
- 该策略支持开发靶向疟原虫和蚊唾液蛋白的新型疟疾疫苗
核心结论
- PfAg嵌合肽免疫可同时靶向PfCSP和AgTRIO,并在小鼠模型中显著改善疟疾感染后的生存。
研究设计与样本
- 研究构建含PfCSP和AgTRIO片段的嵌合肽PfAg,免疫C57BL/6近交系和CD-1远交系小鼠后评估体液免疫及感染蚊暴露后的生存。
主要发现
- PfAg免疫小鼠产生针对PfCSP和AgTRIO的强效体液反应。
- 经表达PfCSP的伯氏疟原虫感染蚊暴露后,PfAg免疫的C57BL/6和CD-1小鼠生存率显著优于对照。
临床怎么用
- 提示同时靶向疟原虫CSP和蚊唾液蛋白AgTRIO可能成为疟疾疫苗开发的新方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malaria begins when an infected mosquito injects saliva containing Plasmodium sporozoites into the host skin. The immune response against a mosquito saliva protein, AgTRIO, reduces Plasmodium infection and can work in combination with antibody against the Plasmodium circumsporozoite protein (CSP). We have now developed a chimeric peptide, PfAg, containing regions from Plasmodium falciparum CSP (PfCSP) and AgTRIO. Mice administered PfAg generated robust humoral responses against both PfCSP and AgTRIO. After exposure to PfCSP-expressing Plasmodium berghei-infected mosquitoes, PfAg-immunized inbred C57BL/6 and outbred CD-1 mice had significantly improved survival compared with control animals. These data will aid in the development of a new malaria vaccine.
引用
- Chuang YM, Ledizet M, Mattessich M, et al. A Multivalent Peptide Vaccine Against Malaria, Targeting Plasmodium Circumsporozoite Protein and Mosquito AgTRIO. J Infect Dis. 2026. PMID: 40804022. doi:10.1093/infdis/jiaf432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。